Text Box: 2002 Cancer Program Annual Report

 

 

Home

Chairman's Letter

Primary Cancer Site

Tabulation & Service

Area Distribution

 

2002 CMC Cancer

Registry Report

 

Most Common

Cancer Site

Distribution By Sex

 

Non-Hodgkin

Lymphoma

 

2002-2003 CMC

Cancer Committee

Membership

 

Contact Numbers

Text Box: NON-HODGKIN LYMPHOMA

 

Text Box: Radiation 20%

Text Box: 2002 CMC NON-HODGKIN LYMPHOMA TREATMENT GRAPH Text Box: By Howard J. Lewis, MD Radiation Oncologist Malignant Lymphomas comprise less than 5% of adult cancers but as a group encompass a very large variety of clinical presentations as they consist of more than 20 pathological subtypes and can arise in virtually any organ. Chemotherapy is the mainstay of treatment although occasionally radiation may be used as an adjunct to reduce overall recurrences and as sole treatment in very limited, favorable presentations. Recent important advances include the increasingly widespread use of monoclonal antibodies (Rituxin), and systemic radioimmunotherapeutic agents (Zevalin and Bexar).   Cumberland Medical Center’s survey of 2002 Non-Hodgkin lymphomas included both limited presentations (maltoma, follicular lymphoma), as well as half the patients having aggressive histologies (diffuse large cell). Almost all patients who receive chemotherapy do so in the private office setting, which would not be reflected in the cancer registry. Follow up data from 1998 indicates roughly 2/3 of patients are alive without disease, consistent with other reported outcomes for lymphoma treatment.  

Text Box: Chem/Rad 10%

Text Box: Surg/Chemo 20%

Text Box: Chemotherapy 20%

Text Box: Chemo/Rad/Hor 10%

Text Box: No Known Treatment 10%  

Text Box: Surgery 10%

 

 

Text Box: Mortality in Non-Hodgkin Lymphoma, CMC vs US   CMC: 1998 4-year observed survival rate: 60%*             Median months of survival: 47.50             Standard deviation: 26.70             Average age at diagnosis: 66.60             Median age at diagnosis: 68.00             Total number of patients observed: 10 US:      1992-1997 5-year relative survival rate: 53%**   *This study is not statistically significant because the number of patients observed is so small. Both analytic and non-analytic cases are included in the study.   **”Trends in Five-Year Relative Survival Rates by Year of Diagnosis, 1992-1997”, Cancer Facts & Figures 2002, p.18, American Cancer Society.  

 

Text Box: Tongue 10%

Text Box: Sinuses 10%

Text Box: Lymph Nodes 20%

Text Box: Lung 10%

Text Box: Colon 10%

 

Text Box: Small Intestine 20%

Text Box: 2002 CMC NON-HODGKIN LYMPHOMA SITES OF ORIGIN

Text Box: Bone Marrow 20%

 

 

 

 

 

 

 

 

Text Box: 2002 CMC NON-HODGKIN'S LYMPHOMA HISTOLOGY

Text Box: 2002 CMC NON-HODGKIN LYMPHOMA INCIDENCE IN FEMALES

 

 

 

 

 

 

 

Text Box: Mature T-cell lymphoma

 

 

Text Box: Mucosal-associated lymphoid tissue (MALT) lymphoma

 

 

Text Box: Small B-cell lymphoma

Text Box: Follicular small cleaved cell lymphoma

Text Box: Diffuse mixed cell lymphoma

Text Box: Diffuse B-cell lymphoma (50 %)

 

 

Text Box: 2002 CMC NON-HODGKIN LYMPHOMA INCIDENCE IN MALES

 

 

 

 

 

 

 

Text Box: CMC

Text Box: 4

Text Box: 4.5

Text Box: 3.5

Text Box: 2.23%

Text Box: 3

Text Box: 3.81%

Text Box: 2.5

Text Box: 2

Text Box: 0.5

Text Box: 1

Text Box: 1.5

Text Box: 3.87%

 

 

 

 

 

 

 

 

 

Text Box: 0

Text Box: US^

Text Box: TN^^

Text Box: 5

Text Box: CMC

Text Box: 3.02%

 

Text Box: 4

Text Box: 4.5

 

Text Box: 3.5

 

Text Box: 3

 

Text Box: 4.42%

Text Box: 3.74%

 

Text Box: 2.5

Text Box: 0

Text Box: 1.5

Text Box: 2

 

Text Box: 0.5

Text Box: 1

 

 

 

Text Box: TN^^

Text Box: Percentage Of All Cancers Text Box: US^ Text Box: Percentage Of All Cancers